Dorinip 500 Injection

Product Description

Dorinip Injection is a targeted therapy in the treatment of cancer has significantly improved the clinical benefits over conventional therapy in indications like head and neck, colorectal etc. Molecular targets such as epidermal growth factor (EGFR) have been well established in the treatment of various solid tumors. Screening for the molecular target and treating the patient with the respective targeted therapeutic agents with or without combination therapy had changed the treatment modalities in recent past. Nimotuzumab is a humanized monoclonal antibody binds to the extracellular domain of EGFR, and consequently inhibits tyrosine kinase activation. Nimotuzumab is the only-affinity optimized anti-EGFR monoclonal antibody exhibits superior safety profile among the class of anti-EGFR agents. Anti-tumor efficacy of nimotuzumab was well correlated with the level EGFR expression in tumors in vitro in vivo.

Broad-Spectrum Infection Control

Dorinip 500 Injection is formulated with Doripenem, renowned for its broad-spectrum antibacterial activity. It is particularly effective in managing severe infections in immunocompromised patients, such as those undergoing cancer treatment. As a liquid injection, it delivers rapid and reliable outcomes under professional healthcare supervision.


Secure and Reliable Sourcing

As an exporter, supplier, and trader of Dorinip 500 Injection in India, we ensure the product reaches healthcare facilities with adherence to international quality and safety standards. Proper storage in a cool, dry location ensures the medication maintains its stability and therapeutic effectiveness.